Daewoong Pharmaceutical's Nabota enters seven Middle Eastern countries, accelerating GCC expansion in Kuwait

Daewoong Pharmaceutical's botulinum toxin Nabota has entered Kuwait, expanding its business footprint in the Middle East. The company has now expanded into seven countries, including Saudi Arabia, the United Arab Emirates (UAE), Türkiye, Qatar, Egypt, Bahrain and Kuwait.
On the 30th, Daewoong Pharmaceutical said it supplied Nabota's first shipment to Kuwait in July. With this move, Nabota has entered five Gulf Cooperation Council (GCC) member states, excluding Oman. The GCC is a cooperative body made up of six Gulf countries: Saudi Arabia, the UAE, Bahrain, Kuwait, Qatar and Oman. The region is seeing growth in the premium aesthetic market, including beauty and plastic surgery, supported by high income levels and strong purchasing power.
The Kuwaiti botulinum toxin market is estimated at about 24 billion won. In particular, consumers there tend to value product quality and brand competitiveness more than price, making the market highly promising for premium toxin products. Online and offline marketing for medical products is also active, drawing attention as a base for global aesthetic companies seeking to enter the Middle East.
Daewoong Pharmaceutical plans to use Kuwait as a key hub for expanding across the GCC market. Together with its local partner, the company will hold an official Nabota launch event in October and also host a symposium for medical professionals. About 200 people, including local medical staff and key figures from the public and private sectors, are expected to attend. Korean dermatology specialists will be invited as speakers to share practical clinical experience and usage cases.
The company will also work to expand contact with local medical professionals. Through a nationwide sales and marketing organization, it will directly manage clients and participate in major academic conferences, while also operating programs for medical professionals such as cadaver training. Its strategy is to continue securing clinical data on Nabota by accumulating investigator-led clinical cases and strengthening cooperation with medical professionals around the world.
Daewoong Pharmaceutical said it plans to expand Nabota's presence in the Middle East based on sales and marketing strategies tailored to each country's market characteristics. Nabota has surpassed cumulative sales of 1 trillion won, and the company expects its Kuwait entry to accelerate business expansion in the Middle East's premium aesthetic market.
Yoon Joon-soo, head of the Nabota business division at Daewoong Pharmaceutical, said, "Entering Kuwait will mark a turning point for Nabota's full-scale push into the GCC market." He added, "Based on local partnerships and product competitiveness, we will secure the trust of medical professionals and consumers and strengthen our brand presence in the Middle East."

[email protected] Jung Sang-hee Reporter